GENE ONLINE|News &
Opinion
Blog

2018-05-01|

May 1, 2004: Broad Institute, the Top Biomedical and Genomic Research Center, Was Officially Launched

by GeneOnline
Share To

On May 1, 2004, the Eli and Edythe L. Broad Institute of MIT and Harvard the Broad Institute, often referred to as the Broad Institute, was formally launched with the funfing from the Eli and Edythe Broad and co-organized by Harvard University and the Massachusetts Institute of Technology. The Broad Institute encourages cooperative research, and has no upper limit to the scale of the budget. The purpose is to integrate knowledge and develop a brand new research cooperation model, to advance genomics medicine. The Broad Institute has became a leading academic institution for genetic and biomedical research. In recent years, one of the most popular CRISPR research has budded from this center.

Reference
https://www.broadinstitute.org/history-leadership/history/history

Image Source
https://www.nytimes.com/2012/01/03/science/broad-institute-director-finds-power-in-numbers.html?_r=0

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
AusBiotech on Funding, Regulatory Navigation, International Expansion, and Clinical Trial Development in Australia’s Biotech Industry
2024-08-22
BioAro and GeneOnline Forge Partnership to Revolutionize Genetic Analysis in Asia Pacific Market
2024-08-13
Reshaping the Genetic Testing Landscape with Quantum Computing: Dr. Anmol Kapoor, CEO of BioAro
2024-08-13
LATEST
TCELS’s Path to a Self-Sufficient Biotech Thailand: Entrepreneurs in Global Competitiveness, Raw Material Exports, and Cosmetic Innovations
2024-10-04
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Eyes on Nvidia: A Strong Investment Prospect, Driving Billions in AI Development and Advanced Infrastructure
2024-09-30
Immunai and AstraZeneca’s $18 Million AI Collaboration to Transform Cancer Drug Development
2024-09-26
Pfizer Pulls Sickle Cell Treatment Over Deadly Complication Risks
2024-09-26
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top